Docusate sodium capsu

DLA Troop Support Medical is soliciting quotations for five packages of Docusate Sodium Capsules (NSN 6505-00-163-7656) under request for quotation SPE2DP27T0088, with quotes due October 19, 2026, which precedes today's date. The procurement uses no set-aside, and quotes must be submitted through DIBBS. The solicitation is a Fast Auto Evaluation issued under the DLA Master Solicitation for Automated Simplified Acquisitions, Revision 105, dated May 20, 2026.

Per the RFQ file summary, delivery is to a facility in Kaiserslautern, Germany, within 20 days, FOB Destination, with inspection and acceptance at destination. The item is an FDA-regulated pharmaceutical: USP 10 mg unit-dose packages of 100 capsules, with a 36-month non-extendable shelf life. Requirements include Medical Marking Standard No. 1, packaging to MIL-STD-2073-1E and commercial specifications, OSHA hazard warning labels, and hazardous material identification and safety data. Buy American Act and Berry Amendment compliance applies. Clauses include safeguarding covered defense information, cyber incident reporting, the covered defense telecommunications prohibition, and U.S.-flag sea transport when applicable. Vendors must register in AMPS to access the Vendor Shipment Module, and payment runs through Wide Area Workflow.

The file summary identifies two qualified manufacturers, The Harvard Drug Group, L.L.C. (CAGE 1LEZ0) and AmerisourceBergen Drug Corp (CAGE 1XUY5), and lists NAICS 325412. The notice carries PSC 6505, Drugs and Biologicals. The source states no evaluation criteria or award value.